Back to Search Start Over

Can pharmacogenetics impact the therapeutic effect of cytarabine and anthracyclines in adult acute myeloid leukaemia patients?: A Serbian experience.

Authors :
Pravdić Z
Suvajdžić-Vuković N
Virijević M
Mitrović M
Pantić N
Sabljić N
Pavlović Đ
Marjanović I
Bukumirić Z
Vidović A
Jaković L
Pavlović S
Gašić V
Source :
Journal of medical biochemistry [J Med Biochem] 2024 Jun 15; Vol. 43 (4), pp. 545-555.
Publication Year :
2024

Abstract

Background: Cytarabine-anthracycline-based induction chemotherapy remains the standard of care for remission induction among patients with newly diagnosed acute myeloid leukaemia (AML). There are remarkable differences in therapy response among AML patients. This fact could be partly explained by the patients' genetic variability related to the metabolic paths of cytarabine and anthracyclines. This study aims to evaluate the effect of variants in pharmacogenes SLC29A1, DCK, ABCB1, GSTM1, and GSTT1, as well as laboratory and AML-related parameters on clinical outcomes in adult AML patients.<br />Methods: A total of 100 AML patients were included in the study. Pharmacogenetic variants SLC29A1 rs9394992, DCK rs12648166, ABCB1 rs2032582, and GSTM1 and GSTT1 gene deletions were detected by methodology based on PCR, fragment analysis and direct sequencing. The methods of descriptive and analytic statistics were used. Survival analysis was done using the Kaplan-Meier method using the Log-Rank test.<br />Results: This is the first study of adult AML pharmacogenetics in the Serbian population. Clinical outcomes in our cohort of AML patients were not impacted by analysed variants in SLC29A1, DCK, ABCB1 and GSTT1, and GSTM1 genes, independently or in combinations. Achievement of complete remission was identified as an independent prognostic indicator of clinical outcome.<br />Conclusions: The population-specific genomic profile has to be considered in pharmacogenetics. Since the data on AML pharmacogenetics in European populations is limited, our results contribute to knowledge in this field and strongly indicate that a high-throughput approach must be applied to find particular pharmacogenetic markers of AML in the European population.<br />Competing Interests: All the authors declare that they have no conflict of interest in this work.<br /> (2024 Zlatko Pravdić, Nada Suvajdžić-Vuković, Marijana Virijević, Mirjana Mitrović, Nikola Pantić, Nikica Sabljić, Đorđe Pavlović, Irena Marjanović, Zoran Bukumirić, Ana Vidović, Ljubomir Jaković, Sonja Pavlović, Vladimir Gašić, published by CEON/CEES.)

Details

Language :
English
ISSN :
1452-8258
Volume :
43
Issue :
4
Database :
MEDLINE
Journal :
Journal of medical biochemistry
Publication Type :
Academic Journal
Accession number :
39139169
Full Text :
https://doi.org/10.5937/jomb0-47459